FDG PET/CT versus somatostatin receptor PET/CT in TENIS syndrome: a systematic review and meta-analysis

Differential Tumor Biology Between Locoregional and Distant Metastasis in a TENIS Patient with Tyrosine Kinase Inhibitor–Resistant Recurrent Disease: Comparative Evaluation with18F-FDG,68Ga-DOTATATE, and68Ga-PSMA-11 PET/CT

“…68 Ga-DOTATOC/TATE-PET/CT can be used for visualization of SSTR-2 expressing lesions. However, not all patients with TENIS lesions express SSTR-2 [6,7,8]. PSMA expression in TENIS for potential treatment options is confirmed by recent studies in differentiated thyroid cancer [10,11,12].…”

“…Silberstein in his recent publication stated physicians caring for patients with the TENIS syndrome are urged to enter them in clinical therapeutic studies whenever possible [5]. The TENIS tumors show variable expression of somatostatin receptors-SSTR-2 on their cell surface [6,7,8] or PSMA in tumor neovasculature on the apical surface of endothelial cells [9]. 68 Ga-DOTATOC/TATE-PET/CT can be used for visualization of SSTR-2 expressing lesions.…”

Other Positron Emission Tomography/Computed Tomography Tracers in Differential Thyroid Carcinoma ¡beyond the Use of 2-[18f]fdg

“…As an uptake mechanism, it has been described that the cells in DTC associated with TENIS syndrome can show SSTR1 in 88.8 % of cases followed by SSTR3 in 55.5 %, SSTR2 in 44.4 %, SSTR5 in 33.3 %, and SSTR4 at 11.2 % [36,37]. Similarly, it has been described that the less aggressive variants present higher SSTR5 expression compared to the more aggressive ones with higher SSTR3 expression [36].…”

“…As a diagnostic tool, in recent years radiopharmaceuticals based on a positron emitter type [ 68 Ga] have been developed, which is associated with a chelator (DOTA) and finally the somatostatin analog (TATE/TOC/NOC/ LAN) [35]. As an uptake mechanism, it has been described that the cells in DTC associated with TENIS syndrome can show SSTR1 in 88.8 % of cases followed by SSTR3 in 55.5 %, SSTR2 in 44.4 %, SSTR5 in 33.3 %, and SSTR4 at 11.2 % [36,37]. Similarly, it has been described that the less aggressive variants present higher SSTR5 expression compared to the more aggressive ones with higher SSTR3 expression [36].…”

“…The use of [ 68 Ga] Ga DOTA-TATE/TOC/ NOC/LAN PET/CT has been described in the staging in case of suspected locoregional and/or distant recurrence in patients diagnosed with DTC with anatomical studies (ultrasound, CT, MRI), [ 131 I] NaI SPECT/CT and 2-[ 18 F] FDG PET/CT are negatives [36,38], determination of locoregional and/or distant disease in patients diagnosed with DTC with radioiodinerefractory thyroid cancer with 2-[ 18 F] FDG PET/CT negative [36,38].…”